Table 1.
Targeted MTM intervention: baseline participant characteristics
| Demographics | All subjects (N = 50) | Control group (n = 25) | MTM group (n = 25) | p value |
|---|---|---|---|---|
| Age (years) | 77.7 ± 6.6 | 79.1 ± 6.9 | 76.3 ± 6.2 | 0.13 |
| Education (years) | 16.1 ± 2.8 | 15.8 ± 3.0 | 16.5 ± 2.5 | 0.34 |
| Female | 35 (70.0) | 17 (68.0) | 18 (72.0) | 0.76 |
| Race | 0.99 | |||
| White | 45 (90.0) | 22 (88.0) | 23 (92.0) | |
| Black or African American | 5 (10.0) | 3 (12.0) | 2 (8.0) | |
| Clinical Dementia Rating | 0.13 | |||
| 0 | 33 (66.0) | 13 (52.0) | 20 (80.0) | |
| 0.5 | 12 (24.0) | 8 (32.0) | 4 (16.0) | |
| 1.0 | 5 (10.0) | 4 (16.0) | 1 (4.0) | |
| Anticholinergic medication use | ||||
| Medication appropriateness index | 12.6 ± 6.3 | 13.0 ± 4.4 | 12.2 ± 7.9 | 0.63 |
| Anticholinergic drug scale | 2.8 ± 1.6 | 2.9 ± 1.3 | 2.8 ± 1.9 | 0.73 |
| Number of anticholinergic drugs | ||||
| 1 | 25 (50.0) | 11 (44.0) | 14 (56.0) | 0.40 |
| ≥2 | 25 (50.0) | 14 (56.0) | 11 (44.0) | |
| Used anticholinergic drugs with moderate/strong activity | 31 (62) | 18 (72) | 13 (52) | 0.14 |
| RAND SF-36 | ||||
| Health domains | ||||
| General health | 67.7 ± 17.9 | 69.4 ± 14.8 | 66.0 ± 20.7 | 0.52 |
| Physical functioning | 67.4 ± 25.6 | 60.4 ± 25.9 | 74.2 ± 23.9 | 0.06 |
| Bodily pain | 66.6 ± 28.1 | 63.1 ± 25.8 | 70.0 ± 30.4 | 0.40 |
| Role limitations, physical | 53.1 ± 38.8 | 50.0 ± 33.8 | 56.3 ± 43.8 | 0.58 |
| Mental health | 82.6 ± 13.0 | 87.1 ± 9.4 | 78.2 ± 14.6 | 0.02 |
| Vitality | 56.1 ± 23.2 | 57.3 ± 23.2 | 55.0 ± 23.7 | 0.73 |
| Social functioning | 80.1 ± 22.7 | 80.7 ± 23.0 | 79.5 ± 22.8 | 0.85 |
| Role limitation, emotional | 81.3 ± 29.9 | 84.7 ± 21.9 | 77.8 ± 36.3 | 0.43 |
| Component scores | ||||
| Physical health | 63.8 ± 22.5 | 60.7 ± 19.1 | 66.8 ± 25.3 | 0.35 |
| Mental health | 75.0 ± 17.8 | 77.5 ± 13.6 | 72.7 ± 21.0 | 0.35 |
Data presented as mean ± SD or N (%)
MTM medication therapy management, SF-36 Short Form Health Survey